48 Infos zu Frédéric Triebel

10 Aktuelle Nachrichten

Primée par l'Anvar, la technologie d'Immutep repose sur les travaux du professeur Frédéric Triebel (université Paris-11) et du groupe suisse ...

Independent Non-Executive Deputy Chairman of the Board. Deanne Miller. Chief Operating Officer, General Counsel, Company Secretary. Frederic Triebel.

(GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima's...

Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima's Chief Scientific Officer and Medical ...

2 Profile in Sozialen Netzwerken

Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his discovery of the LAG3 immune control mechanism. Triebel ...

1 Business-Profile

Retrouvez la biographie, l'interview, les coordonnées, les mandats ainsi que toutes les informations concernant Frederic TRIEBEL sur Verif.com

1 Firmen-Mitarbeiter

Frédéric Triebel, MD Ph.D. founded Immutep S.A. in and served as its Scientific and Medical Director from He was appointed as Immutep's (formerly ...

1 Infos zur Ausbildung

Founder of Immutep SAS, Frédéric Triebel is Chief Scientific & Medical Officer at Immutep Ltd. and Co-Chief Executive Officer for Immutep SAS . He previously...

5 Bücher zum Namen

Monsieur Engel Frederic Triebel, Secretaire du College des Accises Generales de S. A. E. de Saxe An den Accis-Inspector Triebel zu Leipzig. « A Mens: ...

Monsieur Engel Frederic Triebel, Secretaire du College des Accises Generales de S. A. E. de Saxe. An An den Accis-Inspector Triebel zu Leipzig. - A Mens: ...

Comme l'a déclaré le directeur général d'Immutep, Frederic Triebel : « Il y a cinq ans, personne n'aurait envisagé d'aller produire en Chine. Mais aujourd'hui, il ...

... NEIMARK, P.L.L.G, ATTORNEYS AT LAW Suite Ninth Street, N.W. Washington, DC ,In re Application of Frederic Triebel Application No.

1 Allgemeine Veröffentlichungen

Genomic organization of the human LAG-3/CD4 locus. D. Bruniquel ,; N. Borie &; Frédéric Triebel. Immunogenetics volume 47, pages96–98(1997)Cite this ...

2 Meinungen & Artikel

Frédéric Triebel (20. November 1954) ist ein Französisch Immunologe , die am besten für seine Entdeckung des bekannte LAG3 ...

Margo Roberts, Sven Kili, Susan Solomon, Laszlo Radvanyi, Jon Wigginton, Frédéric Triebel, Stephen Badylak, Keith Thompson. Disciplines. Life Science.

23 Webfunde aus dem Netz

... Oct. 31, (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima's ...

Frédéric Triebel, French immunologist. Achievements include research in cloning and identification of several human genes with an important role for mounting...

Frédéric Triebel founded Immutep SAS. Dr. Triebel is Executive Director & Chief Scientific Officer at Immutep Ltd. and Co-Chief Executive Officer of Immutep...

Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his discovery of the LAG3 immune control mechanism. Triebel ...

... results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress.

EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical...

Dr Frédéric Triebel - Latest in R&D and production of mAbs and next generation tecchnology

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in...

IMMP - key executives, insider trading, ownership, revenue and average growth rates. Detailed company description & address for Immutep Ltd. ADR.

Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64); Mr. Jay R. Campbell, Chief Bus. Officer; Mr. David Fang, Fin. Director & Assistant How has IMMUTEP LTD/S's stock been impacted by COVID-19 (Coronavirus)? Do Wall Street analysts recommend investors buy shares of IMMUTEP LTD/S? What price target have analysts set for IMMP? What are Wall Street analysts saying about IMMUTEP LTD/S stock? Has IMMUTEP LTD/S been receiving favorable news coverage? Who are some of IMMUTEP LTD/S's key competitors? What other stocks do shareholders of IMMUTEP LTD/S own? Who are IMMUTEP LTD/S's key executives? What is IMMUTEP LTD/S's stock symbol? How do I buy shares of IMMUTEP LTD/S? Mehr auf marketbeat.com ansehen Mehr anzeigen Weniger anzeigen

... molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.

Prima gets a grant for its immune research with Monash University

Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late read this article along with other...

Marie-Noëlle Avice, Marika Sarfati, Frederic Triebel, Guy Delespesse and Christian E. Demeure. J Immunol March 1, 1999, 162 (5) ;. Marie-Noëlle ...

... (pDCs): a molecular target for the restoration of active antitumor immunity. Chiara Castelli, Frédéric Triebel, Licia Rivoltini, Chiara Camisaschi.

PRRUF - key executives, insider trading, ownership, revenue and average growth rates. Detailed company description & address for Immutep Ltd..

On paper it looks like an intriguing proposition: you take a blockbuster cell-surface protein target currently addressable only with antibodies, hit it with a...